

**RECEIVED  
CENTRAL FAX CENTER**

Attorney Docket No.: 5835.210-US

**JUN 28 2006**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgård-Frantzen et al Confirmation No: 7464

Serial No.: 10/820,200

Group Art Unit: 1653

Filed: April 7, 2004

Examiner: Monshipouri, Maryam

For: Fungamyl-like Alpha-Amylase Variants

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Monshipouri, Maryam, fax number (571)273-8300.

Respectfully submitted,



Date: June 28, 2006

Lourdes Ayala  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

**RECEIVED  
CENTRAL FAX CENTER****JUN 28 2006****PATENT**

Attorney Docket No.: 5835.210-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgård-Frantzen et al Confirmation No: 7464

Serial No.: 10/820,200

Group Art Unit: 1653

Filed: April 7, 2004

Examiner: Monshipouri, Maryam

For: Fungamyl-like Alpha-Amylase Variants

**AMENDMENT FEE TRANSMITTAL**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed January 18, 2006.

It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from May 18, 2006 to July 18, 2006. The required fee for the extension is estimated to be \$1,020.

No additional claims fee is required.

Please charge the required extension and claims fees, estimated to be \$1,020, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 28, 2006

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
600 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-009706/30/2006 WARDEL1 00000077 501701 10820200  
01 FC:1253 1020.00 DA

**RECEIVED  
CENTRAL FAX CENTER**

**JUN 28 2006**

Attorney Docket No.: 5835.210-US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgård-Frantzen et al Confirmation No: 7464

Serial No.: 10/820,200

Group Art Unit: 1653

Filed: April 7, 2004

Examiner: Monshipouri, Maryam

For: Fungamyl-like Alpha-Amylase Variants

**AMENDMENT FEE TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed January 18, 2006.


It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from May 18, 2006 to July 18, 2006. The required fee for the extension is estimated to be \$1,020.

No additional claims fee is required.

Please charge the required extension and claims fees, estimated to be \$1,020, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 28, 2006

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

**RECEIVED  
CENTRAL FAX CENTER**

Attorney Docket No.: 5835.210-US

**JUN 28 2006**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgård-Frantzen et al Confirmation No: 7464

Serial No.: 10/820,200

Group Art Unit: 1653

Filed: April 7, 2004

Examiner: Monshipouri, Maryam

For: Fungamyl-like Alpha-Amylase Variants

**AMENDMENT UNDER 37 C.F.R. 1.111**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed January 18, 2006, please amend the above-identified application as follows:

**Amendments to the claims** are reflected in the listing of claims, which begins on page 2 of this document.

**Remarks and arguments** begin on page 7 of this document.